Five Prime Therapeutics

Startup Walking Fish nabs $50M to run with B cell therapies for cancer & more

Walking Fish Therapeutics is developing cell therapies from B cells, a type of immune cell that produces prodigious amounts of proteins. Cancer, autoimmune disease, and regenerative medicine are among the targets of the preclinical-stage biotech, which unveiled $50 million in funding.

Amgen in $1.9bn swoop for Five Prime and its gastric cancer drug

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline. The big pharma swooped in after the California biotech reported promising phase 2 trial results from bemarituzumab in November. The phase 2 FIGHT trial testing bemarituzumab plus chemotherapy as a front-line therapy for advanced gastric …

Amgen in $1.9bn swoop for Five Prime and its gastric cancer drug Read More »

Amgen’s $1.9B Five Prime deal adds to cancer drug pipeline and Asia strategy

The acquisition brings Amgen a novel Phase 3-ready drug for gastric cancers. For Five Prime Therapeutics, the deal is a lifeline following a series of clinical and financial setbacks that left much of the biotech’s fortunes resting on its lead antibody drug.

Five Prime eyes financing after positive results with stomach cancer drug

Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not seen since 2018. The phase 2 FIGHT trial testing bemarituzumab plus chemotherapy as a front-line therapy for advanced gastric and gastroesophageal junction cancer met all its efficacy …

Five Prime eyes financing after positive results with stomach cancer drug Read More »